Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Antiviral hepatitis and systemic therapies for hepatocellular carcinoma (HCC) remarkably progressed in the recent 10 years. This study aimed to reveal the actual transition and changes in the prognosis and background liver disease in non-advanced HCC in the past 20 years.
Methods: This retrospectively recruited 566 patients who were diagnosed with non-advanced HCC from February 2002 to February 2022. The prognosis was analyzed by subdividing according to the diagnosis date (period I: February 2002-April 2009 and period Ⅱ: May 2009-February 2022).
Results: Patients in period II (n = 351) were significantly older, with lower albumin-bilirubin (ALBI) scores and alpha-fetoprotein (AFP) and more anti-viral therapy, systemic therapy, and hepatic arterial infusion chemotherapy as compared with those in period I (n = 215). The etiology ratio of the background liver disease revealed decreased hepatitis C virus from 70.6% to 49.0% and increased non-B, non-C from 17.7% to 39.9% from periods I to Ⅱ. The multivariate analysis revealed older age and higher ALBI score in Barcelona Clinic Liver Cancer (BCLC) 0/A stage, AFP of >20 ng/mL, and higher ALBI score in BCLC B stage as independent prognosis factors. Fine-Gray competing risk model analysis revealed that liver-related deaths significantly decreased in period II as compared to period I, especially for BCLC stage 0/A (HR: 0.656; 95%CI: 0.442-0.972, P = 0.036).
Conclusion: The characteristics of patients with non-advanced HCC have changed over time. Appropriate background liver management led to better liver-related prognoses in BCLC 0/A.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10919582 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297882 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Minimally invasive liver surgery for perihilar and intrahepatic cholangiocarcinoma: systematic review and meta-analysis of comparative studies.
Surg Endosc
September 2025
Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
Background: The implementation of minimally invasive liver surgery (MILS) for perihilar (PHC) and intrahepatic cholangiocarcinoma (IHC) remains limited and a systematic review including only comparative studies of MILS versus the open approach is lacking. This systematic review and meta-analysis aimed to assess the safety and efficacy of minimally invasive surgery in patients with hilar and intrahepatic cholangiocarcinomas.
Methods: Systematic review in the PubMed, Embase, and Cochrane databases for original studies comparing at least five patients undergoing MILS with open liver surgery for PHC and IHC.
Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation.
J Am Coll Cardiol
September 2025
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region of China; Advanced Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region of China
Background: There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population.
Objectives: In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM.
Methods: We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database.
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design.
BMJ Open
September 2025
Department of Interventional Radiology, The First Hospital of China Medical University, Shenyang, Liaoning, China
Background: Advanced-stage hepatocellular carcinoma (HCC) with high tumour burden and portal vein tumour thrombus (PVTT) is usually associated with poor survival outcomes. Rapid tumour control usually benefits long-term outcomes, which could be hardly achieved by solely systematic targeted and immunotherapy in current guidelines. Hepatic arterial infusion chemotherapy (HAIC) is reported as an effective intervention for rapid decrease of tumour burden.
View Article and Find Full Text PDFThe effect of muscle quality index on the risk of adverse health outcomes: a prospective cohort study of 355,209 adults.
Am J Clin Nutr
September 2025
Department of Geriatrics, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou 3100003, China. Electronic address:
Background: Muscle quality index (MQI), a new metric for assessing sarcopenia, reflects the functional capacity of muscle. However, the associations between MQI and adverse health outcomes and the corresponding mechanisms are not well understood.
Objective: We aimed to prospectively evaluate the associations of MQI with risk of nine adverse health outcomes (ie, osteoarthritis, cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), respiratory disease, chronic kidney disease (CKD), liver disease, dementia, depression, and all-cause mortality), as well as the mediating role of metabolomics in these associations.
Supplementary Material for Projected Global Clinical, Humanistic, and Economic Impact of Metabolic Dysfunction-Associated Steatohepatitis (MASH): The Cost of Inaction Based on Data from Nine Countries.
Clin Gastroenterol Hepatol
September 2025
The Global NASH/MASH Council, Washington, DC, United States; Gastroenterology Section, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia; Liver, Digestive, and Lifestyle Health Research Section, and Organ Transplant Center of Excellence, King Faisal Sp
Background And Aim: Although the clinical burden of MASH is well known, its economic burden is less well described. We estimated MASH's economic burden in several regions of the world including the US, Germany, Spain, France, Italy, and United Kingdom (UK), Japan, Saudi Arabia, and Brazil over the next two decades.
Methods: A one-year cycle Markov model projected MASH progression from 2021 to 2040, incorporating 2020 prevalent cases and annual incident cases (2021-2040).